• Japanese
  • Korean
  • Chinese
Cover Image

Human Insulin Market in China 2011-2015

Abstract

TechNavio's analysts forecast the Human Insulin market in China to grow at a CAGR of 19.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the diabetic population in China. The Human Insulin market in China has also been witnessing increased number of corporate agreements. However, the high cost of human insulin could pose a challenge to the growth of this market.

TechNavio's report, the Human Insulin Market in China 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on China; it also covers the Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, and Tonghua Dongbao Pharmaceutical Co. Ltd. The report also includes other vendors such as Abbott Laboratories Inc., Bayer Healthcare AG, Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., Pfizer Inc., and Zhuhai United Laboratories Inc.

Key questions answered in this report:

  • What will the market size be in 2015 and at what rate will it grow?
  • What key trends is this market subject to?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the opportunities and threats faced by each of these key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

Table of Contents

01. Executive Summary

02. Introduction

03. Market Coverage

  • Market Overview
  • Key Offerings

04. Market Landscape

  • 04.1. Insulin Market in China
  • 04.2. Human Insulin Market in China
    • Market Size
    • Market Forecast
    • Five Forces Analysis

05. Rate of Incidence and Prevalence

  • Diabetes

06. Vendor Landscape

  • Vendor Strategies

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis

  • 13.1. Novo Nordisk A/S
    • Business Overview
    • SWOT Analysis
  • 13.2. Sanofi SA
    • Business Overview
    • SWOT Analysis
  • 13.3. Eli Lilly and Co.
    • Business Overview
    • SWOT Analysis
  • 13.4. Tonghua Dongbao Pharmaceutical Co. Ltd.
    • Business Overview
    • SWOT Analysis

14. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Insulin Market in China 2011-2015 (US$ million)
  • Exhibit 2: Insulin Market in China by Product Segmentation
  • Exhibit 3: Insulin Market in China by Category Segmentation 2011
  • Exhibit 4: Insulin Market in China 2011-2015 by Revenue Segmentation (US$ million)
  • Exhibit 5: Insulin Market in China 2011-2015 by Segmentation (percentage)
  • Exhibit 6: Human Insulin Market in China 2011-2015 (US$ million)
  • Exhibit 7: Human Insulin Market in China by Vendor Segmentation 2011
Show More
Pricing
Get Notified
Email me when related reports are published